AORTIC DISEASE • SURGERY • ENDOVASCULAR TECHNOLOGY
The Changing Future of Aortic Aneurysm Repair
Open surgery remains essential for much disease of the ascending aorta, but hybrid and endovascular technologies are steadily expanding what specialists can treat—and how.
MKP EXPLAINER • OCTOBER 6, 2026
Why the ascending aorta is difficult
Endovascular stent grafts transformed treatment of many descending thoracic and abdominal aortic aneurysms. The ascending aorta and arch are harder: they sit close to the aortic valve, coronary arteries and vessels supplying the brain, while experiencing powerful pulsatile forces. For many ascending-aortic aneurysms that require intervention, open surgical replacement therefore remains the established approach.
When does an ascending aneurysm need surgery?
The 2022 ACC/AHA aortic-disease guideline recommends intervention for sporadic aortic-root or ascending-aortic aneurysm at 5.5 cm in the standard setting, while experienced multidisciplinary aortic centers may reasonably intervene at 5.0 cm in selected patients. Rapid growth—at least 0.5 cm in one year or 0.3 cm per year across two consecutive years for sporadic aneurysms—is also important. Genetics, valve disease, family history, symptoms and body size can change decision-making.
2026: endovascular treatment reaches the arch
In April 2026, the FDA approved the NEXUS Aortic Arch Stent Graft System for endovascular treatment of chronic dissections involving the aortic arch in patients at high risk for open surgical repair who have appropriate anatomy. This is a significant step for selected arch disease—but it is not a general catheter-based replacement for elective open repair of ordinary ascending-aortic aneurysms.
A hybrid approach to acute dissection
In June 2026, the FDA approved the AMDS Hybrid Prosthesis for a specific group of patients with acute DeBakey Type I aortic dissection with malperfusion who are undergoing open surgical repair within 14 days of diagnosis. The device combines open surgery with a stented component intended to address disease extending through the arch and downstream aorta.
What comes next?
Engineers and surgeons are working toward devices capable of treating more proximal aortic disease with less invasive techniques. The challenge is not simply making a smaller graft; future systems must seal securely while preserving blood flow to the heart and brain and surviving enormous mechanical stresses. Patient anatomy also varies substantially, so advanced imaging, planning and specialized centers remain central to progress.
Surveillance is part of the technology story
Better repair is only one side of modern aortic care. CT, MRI and echocardiography allow clinicians to track aortic dimensions over time. Current guidance emphasizes consistent measurement techniques and surveillance because growth rate can influence the timing of intervention. Preventing an emergency by recognizing meaningful change early remains one of the most powerful tools available.
MKP takeaway
Aortic repair is moving toward a broader spectrum: conventional open operations, hybrid procedures and fully endovascular approaches for carefully selected anatomy. In 2026, that future is visibly arriving—but the technology is disease- and anatomy-specific, and open surgery remains the standard for many ascending-aortic aneurysms.
Sources
U.S. Food and Drug Administration premarket approvals for the NEXUS Aortic Arch Stent Graft System (April 2026) and AMDS Hybrid Prosthesis (June 2026); ACC/AHA 2022 Guideline for the Diagnosis and Management of Aortic Disease.
FDA: NEXUS approval →
FDA: AMDS approval →
AHA: aortic disease guideline →
This article is educational and is not individualized medical advice.